This observational multicenter study will evaluate the differences in progression-free survival defined in specific subgroups of participants with metastatic colorectal cancer receiving bevacizumab (Avastin). Further, safety and efficacy in daily routine will be assessed.
Study Type
OBSERVATIONAL
Enrollment
3,003
Administration of treatment will be as used in normal daily routine under local labeling.
Median Progression-Free Survival Time in Defined Participant Subgroups as Assessed by Response Evaluation Criteria In Solid Tumors (RECIST)
Time frame: Baseline up to 5 years
Percentage of Participants by Prognostic Factors
Time frame: Baseline up to 5 years
Percentage of Participants by Carcinoembryonic Antigen Tumor Marker
Time frame: Baseline
Percentage of Participants by Cancer Antigen 19-9 Tumor Marker
Time frame: Baseline
Percentage of Participants by Eastern Cooperative Oncology Group (ECOG) Performance Status
Time frame: Baseline
Percentage of Participants by Comorbidity Index as per Carlson Method
Time frame: Baseline
Percentage of Participants by RAS Mutation Status
Time frame: Baseline
Percentage of Participants by Cancer Metastasation Status
Time frame: Baseline
Percentage of Participants According to Previous Treatment Regimen of Bevacizumab
Time frame: Baseline
Progression-Free Survival as Assessed by RECIST (Overall)
Time frame: Baseline up to 5 years
Overall Survival in Daily Routine Practice
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline up to 5 years
Overall Survival in Defined Participant Subgroups in Daily Routine Practice
Time frame: Baseline up to 5 years
Percentage of Participants Showing Overall Response in Daily Routine Practice as Assessed by RECIST
Time frame: Baseline up to 5 years
Number of Treatment Application Schemes of Bevacizumab Daily Routine Practice
Time frame: Baseline up to 5 years
Number of Participants With Adverse Event
Time frame: Baseline up to 5 years
Number of Participants With Reason for Bevacizumab Treatment Modifications and Discontinuation in Defined Participant Subgroups
Time frame: Baseline up to 5 years
Total Cumulative Therapy Dose of Bevacizumab
Time frame: Baseline up to 5 years
Percentage of Participants With Treatment Success
Time frame: Baseline up to 5 years
Percentage of Participants With Resection
Time frame: Baseline up to 5 years
Number of Physicians Satisfied With Treatment
Time frame: Baseline up to 5 years
Percentage of Participants Without Resection by Reason
Time frame: Baseline up to 5 years
Percentage of Participants With Follow-Up therapy
Time frame: Baseline up to 5 years
Percentage of Participants in Defined Participant Subgroups Showing Overall Response in Daily Routine Practice as Assessed by RECIST
Time frame: Baseline up to 5 years